HSA Grants Interim Authorisation for LAGEVRIO (Molnupiravir) for Treatment of COVID-19 Infection
Guest Contributor
The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee, has granted interim authorisation under the Pandemic Special Access Route (PSAR) for MSD’s LAGEVRIO (molnupiravir) on 19 April…
Melissa Fann
